BACKGROUND: Angiotensin-converting enzyme (ACE) 2 is a novel homologue of ACE. It metabolizes angiotensin (Ang)II to Ang-(1-7). This study aims to investigate the diagnostic and prognostic potency of circulating ACE2 activity in patients with heart failure (HF) from Chagas' disease (CD). METHODS AND RESULTS: Blood samples were obtained from 111 CD patients and 40 age- and gender-matched healthy subjects. The CD patients were further subdivided according to their New York Heart Association classification. ACE2 activity was significantly increased in CD patients with HF, but not in patients without systolic dysfunction. Moreover, plasma ACE2 activity was significantly correlated with their clinical severity and echocardiographic parameters. Importantly, the potency of circulating ACE2 activity in CD patients was equally potent as that of B-type natriuretic peptide to predict cardiac death and heart transplant. Most importantly, patients with both parameters elevated were on a 5-fold higher risk to reach an endpoint than patients with increase in only 1 of the 2 parameters. CONCLUSIONS: Determination of ACE2 activity may provide a new and important diagnostic and prognostic marker for patients with CD. ACE2 activity and BNP concentration have additive predictive value and may be used in combination to offer a new dimension of prediction in HF. Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.
BACKGROUND:Angiotensin-converting enzyme (ACE) 2 is a novel homologue of ACE. It metabolizes angiotensin (Ang)II to Ang-(1-7). This study aims to investigate the diagnostic and prognostic potency of circulating ACE2 activity in patients with heart failure (HF) from Chagas' disease (CD). METHODS AND RESULTS: Blood samples were obtained from 111 CDpatients and 40 age- and gender-matched healthy subjects. The CDpatients were further subdivided according to their New York Heart Association classification. ACE2 activity was significantly increased in CDpatients with HF, but not in patients without systolic dysfunction. Moreover, plasma ACE2 activity was significantly correlated with their clinical severity and echocardiographic parameters. Importantly, the potency of circulating ACE2 activity in CDpatients was equally potent as that of B-type natriuretic peptide to predict cardiac death and heart transplant. Most importantly, patients with both parameters elevated were on a 5-fold higher risk to reach an endpoint than patients with increase in only 1 of the 2 parameters. CONCLUSIONS: Determination of ACE2 activity may provide a new and important diagnostic and prognostic marker for patients with CD. ACE2 activity and BNP concentration have additive predictive value and may be used in combination to offer a new dimension of prediction in HF. Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.
Authors: Sreedhar Bodiga; Jiu Chang Zhong; Wang Wang; Ratnadeep Basu; Jennifer Lo; George C Liu; Danny Guo; Steven M Holland; James W Scholey; Josef M Penninger; Zamaneh Kassiri; Gavin Y Oudit Journal: Cardiovasc Res Date: 2011-02-01 Impact factor: 10.787
Authors: Zhili Shao; Kevin Shrestha; Allen G Borowski; David J Kennedy; Slava Epelman; James D Thomas; W H Wilson Tang Journal: J Card Fail Date: 2013-09 Impact factor: 5.712
Authors: Zhili Shao; Andres Schuster; Allen G Borowski; Akanksha Thakur; Lin Li; Wai Hong Wilson Tang Journal: Transl Res Date: 2019-07-04 Impact factor: 7.012
Authors: Silvia A Longhi; Silvia B Brandariz; Sonia O Lafon; Leticia L Niborski; Alejandro O Luquetti; Alejandro G Schijman; Mariano J Levin; Karina A Gómez Journal: Am J Trop Med Hyg Date: 2012-08 Impact factor: 2.345